Maharashtra Fda Restricts Disprin Sales

Image
Our Correspondent BUSINESS STANDARD
Last Updated : Jan 28 2013 | 1:12 AM IST

The commissioner, Food and Drugs Administration (FDA) of Maharashtra, is learnt to have issued orders to stockists restricting them from marketing Disprin tablets in the state.

The order comes in the wake of reports that Reckitt Benckiser, the manufacturer, is marketing paracetamol and aspirin-based formulations under the same brand name.

Reckitt Benckiser used to manufacture an aspirin-based formulation under the brand name Disprin, but later discontinued the product and started marketing a paracetamol-based formulation under the same brand name.

Also Read

Subsequently, Reckitt Benckiser also introduced the original aspirin-based formulation under the same name, creating confusion in the market.

Legal experts have argued that marketing two entirely different formulations under the same brand name is against the prevailing laws of the land.

They pointed out that Reckitt Benckiser had launched Acetyl Salicylic Acid (Aspirin) under the brand name Disprin globally in 1948.

It was initially launched as a pain killer, but after researchers confirmed its utility in dilating blood vessels for heart patients, it was promoted as such.

The US Food and Drugs Administration department sought public opinion before approving it as a useful cardiovascular drug.

Further, research confirmed its utility in cerebro-vascular disorders and also in rheumatoid arthritis.

The US FDA thus approved the drug aspirin under the brand name Disprin with different labels having different colours and specifications for use in cardio-vascular, cerebro-vascular and rheumatoid diseases.

In India, the same company launched aspirin as Disprin, but recently changed the formulation to paracetamol.

The Maharashtra FDA has expressed surprise that the Drug Controller of neighbouring Karnataka, where the manufacturing unit of Reckitt Benckiser is based, is allowing the manufacture of different formulations under the same brand name.

Commissioner FDA, Maharashtra, Uttam Khobragade, confirmed that stockists have been asked to hold back stocks of Disprin until the matter is resolved.

He said he had also written to his counterparts in Karnataka and asked them to look into the issue.


*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 03 2002 | 12:00 AM IST

Next Story